Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
Journal of Community Hospital Internal Medicine Perspectives, 2018 Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation ...
Adnan Asif Parvez Ghias +3 more
doaj +1 more source
Clinical and Translational Science, 2022 For the long‐term efficacy of dry eye disease treatment, relieving underlying inflammation is necessary. Imatinib mesylate is a novel ophthalmic formulation of imatinib mesylate, which is expected to alleviate inflammation by inhibiting the discoidin ...
Joo Young Na +7 more
doaj +1 more source
Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]
, 2008 Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad +4 more
core +1 more source
Erratum to: Exploiting the promiscuity of imatinib [PDF]
BMC Biology, 2010 An error in the PDB code occurred in the article published in the Journal of Biology [1]. In the legend to Figure One, instead of 1FW3, the correct PDB code is 3FW1.
Lee, Shun J, Wang, Jean YJ
openaire +5 more sources
Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro. [PDF]
PLoS ONE, 2011 Imatinib Mesylate (Gleevec) is a drug that potently counteracts diabetes both in humans and in animal models for human diabetes. We have previously reported that this compound in human pancreatic islets stimulates NF-κB signaling and islet cell survival.
Dariush Mokhtari +3 more
doaj +1 more source
Combined population dynamics and entropy modelling supports patient stratification in chronic myeloid leukemia [PDF]
, 2016 Modelling the parameters of multistep carcinogenesis is key for a better understanding of cancer progression, biomarker identification and the design of individualized therapies.
Brehme, Marc +7 more
core +1 more source
BCR::ABL1‐Positive Acute Myeloid Leukemia
American Journal of Hematology, EarlyView.
Alban Canali +3 more
wiley +1 more source
The Journal of Clinical Pharmacology, EarlyView.Abstract Belumosudil is an oral selective rho‐associated coiled‐coil containing protein kinase 2 inhibitor, approved as a treatment for chronic graft‐versus‐host disease. Prior clinical studies demonstrated that coadministration with strong CYP3A4 inducers or proton pump inhibitors requires dose modification of belumosudil.
Olivier Schueller +4 more
wiley +1 more source
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. [PDF]
, 2016 CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue.
Calabretta, Bruno +10 more
core +2 more sources
Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia [PDF]
Oncotarget, Impact journals, 2018, 2019 Background: Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the bcr-abl chimeric oncogene, encoding a 210 kDa protein with constitutive tyrosine kinase activity. In spite of the efficiency of tyrosine kinase inhibitors (TKI; Imatinib), other strategies are explored to eliminate CML leukemia stem cells, such as ...
arxiv